Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | RBP4 | P02753 | 1/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | MGLL | Q99685 | 8/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | BCR | P11274 | 1/20 | 0.43 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23260550 | 0.77 | CHRM2 (0.47) | LMNAHPGDSMN1; SMN2 | |
| SCHEMBL26529969 | 0.77 | CHRM2 (0.52) | LMNAPOLBSMN1; SMN2 | |
| SCHEMBL38663614 | 0.75 | ALDH1A1 (0.52) | LMNAPOLBSMN1; SMN2 | |
| SCHEMBL13503927 | 0.74 | LMNA (0.65) | LMNAPOLBHPGDRBP4HSD11B1 | |
| SCHEMBL14923254 | 0.74 | POLB (0.65) | LMNAPOLBHPGDRBP4HSD11B1 | |
| SCHEMBL38665569 | 0.73 | GRIN2D (0.49) | — | |
| SCHEMBL23260551 | 0.73 | NR2E1 (0.43) | LMNAMGLLSMN1; SMN2 | |
| SCHEMBL38663578 | 0.73 | HRH4 (0.54) | HRH3 | |
| SCHEMBL38662983 | 0.73 | GRIN2D (0.49) | RBP4 | |
| SCHEMBL13504041 | 0.73 | HPGD (0.70) | LMNAPOLBHPGDRBP4HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322715-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322715-A1 | BROAD SPECTRUM ANTI-CANCER COMPOUNDS | YTHDF1, YTHDF3, YTHDF2 | LMNA 3852/4885POLB 2670/4885HPGD 4885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.